[{"indications": "Indications\u00a0\n(From Protein kinase inhibitors: British National Formulary)\nSorafenib, an inhibitor of multiple kinases, is licensed for the treatment of advanced renal cell carcinoma when treatment with interferon alfa or interleukin-2 has failed or is contra-indicated (but see NICE Guidance below). It is also licensed for the treatment of hepatocellular carcinoma.", "name": "SORAFENIB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.5 Other antineoplastic drugs", "Protein kinase inhibitors", "SORAFENIB"], "cautions": "Cautions\u00a0major surgical procedures; cardiac ischaemia; susceptibility\r\nto QT-interval prolongation; interactions: Appendix 1 (sorafenib) ", "side-effects": "Side-effects\u00a0see section 8.1; also diarrhoea, constipation,\r\ndyspepsia, dysphagia, anorexia, hypertension, haemorrhage, flushing,\r\nhoarseness, fatigue, asthenia, depression, peripheral neuropathy,\r\nfever, erectile dysfunction, renal failure, hypophosphataemia, arthralgia,\r\nmyalgia, tinnitus, rash, pruritus, erythema, dry skin, desquamation,\r\nacne, hand-foot skin reaction; less commonly gastro-intestinal perforations, myocardial infarction, congestive heart failure,\r\nhypertensive crisis, interstitial lung disease-like events, reversible\r\nposterior leucoencephalopathy, thyroid dysfunction, and Stevens-Johnson\r\nsyndrome; rarely hepatitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129970.htm", "doses": ["adult over 18 years, 400\u00a0mg\r\ntwice daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless essential\u2014toxicity\r\nin animal studies; see also Pregnancy and Reproductive\r\nFunction"}]